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Background/aim: Recent studies have shown that IL-17-producing CD4+ T helper (Th17) cells play an important role in proinflammatory
processes. In this report we analyzed IL-17, IL-21, and TGF-β serum levels in the peripheral blood of Iranian beta-thalassemia major
patients that clinically exhibited splenectomy and iron overload.
Materials and methods: Blood samples were collected from 43 beta-thalassemia patients and 43 healthy individuals with no history of
malignancies or autoimmune disorders. Then serum levels of IL-17, IL-21, and TGF-β were measured by enzyme linked immunosorbent
assay (ELISA).
Results: The levels of IL-17 (P = 0.005) and TGF-β (P < 0.001) were significantly higher in the thalassemia patients compared to the
healthy control. No significant differences in the level of serum IL-21 was observed between the patients and controls. There were no
significant differences in serum levels of IL-17, IL-21, and TGF-β between patients with high or low serum levels of ferritin.
Conclusion: Multiple blood transfusions cause constant immune stimulation, as a result of repeated exposure to new alloantigens.
This might have significant effects on the stimulation of cytokine producing cells in those patients and cytokine profile can be used as a
related marker for assessing disease severity and consequently therapeutic intervention.
Key words: Beta-thalassemia, interleukin-17, interleukin-21, transforming growth factor beta

1. Introduction
Beta-thalassemia is a congenital hemolytic disorder caused
by a partial or complete deficiency of β-globin chain
synthesis. Patients with beta-thalassemia major suffer
from severe anemia and other serious complications from
early childhood. The disease is treated by chronic blood
transfusion. However, this can cause severe iron overload,
resulting in progressive organ failure (1,2).
Infectious complications and immune abnormalities
have always been considered as causes of morbidity and
mortality in β-thalassemia. A wide range of functional
and quantitative immune alterations have been described
in β-thalassemia patients with multiple transfusions.
These abnormalities seem to be acquired and secondary
to allogenic stimulation of the antibody-producing cells
by continuous blood transfusions, together with iron
overload (3–8).
Two decades ago Mossman and Coffman (for review
see 9) proposed that CD4+ T cells differentiate into two
* Correspondence: davamimh@gmail.com

subsets with reciprocal functions and patterns of cytokine
secretion, termed T-helper 1 (Th1) and Th2 (10). This
paradigm was maintained until 2005, when a third T-cell
subset, known as Th17, was identified (11,12). The main
feature of this subset is its release of interleukin 17 (IL17) (13,14). The role and function of Th17 indicate that
this subset of CD4+ T cells plays a fundamental role in
infiltration and recruitment of inflammatory cells against
intercellular parasites and fungi (15) and recently in certain
Th1 mediated autoimmune diseases such as rheumatoid
arthritis and multiple sclerosis (16). Several recent studies
demonstrated that transforming growth factor beta
(TGF-β) and IL-6, but not IL-23, are critical factors for
murine Th17 cell differentiation in vitro (17,18).
It appears that TGF-β plays an essential role in
dictating whether CD4+ T cells become Treg cells
or Th17 cells. The combination of TGF-β and IL-6
promotes the differentiation of Th17 cells and inhibits
Treg cell differentiation in mice (17,18), whereas TGF-β
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plus retinoic acid inhibits Th17 cell differentiation and
promotes Treg cells (19,20).
It is shown that IL-21 is another cytokine highly
expressed by mouse Th17 cells. IL-21 is induced by
IL-6 in activated T cells, a process that is dependent on
STAT3 but not ROR-gamma. IL-21 potently induces Th17
differentiation and suppresses Foxp3 expression, which
requires STAT3 and ROR-gamma, which is encoded by
Rorc. IL-21 deficiency impairs the generation of Th17
cells and results in protection against experimental
autoimmune diseases (18).
Apart from synthesis by Th17, IL-17 may also be
produced by other cells such as CD8+ T cells, NKT cells,
epithelial cells, and cells from the innate immune system
(for review see 21). It seems IL-17 acts as an interface
between inflammatory response and cell-mediated
immunity in the case of cancer and also in infectious
diseases. Inflammatory reactions are considered a first
line of host immune response against pathogens (22). It
seems the role of IL-17 in recruiting inflammatory cells
and potentiating of this event is necessary. IL-17 and IL-21
are proinflammatory cytokines whose roles in recruiting
inflammatory cells and potentiating of this event should
be considered.
Several factors may be significant in triggering Th17
and consequently the synthesis and release of IL-17 such
as TGF-β, IL-6, progstaglandin E2, IL 21, IL-23, IL-1β,
and TNF-α play major roles in the induction of Th17
differentiation (23–25).
Despite the known roles of IL-17 in enhancing
inflammatory reactions, reports on the role and
involvement of iron overload in Th17 response do not
exist. On the other hand, it is shown that iron directs the
immune response toward a Th2 response pattern, which
is unfavorable for fighting a bacterial or viral infection
(3). Gharagozloo et al. found low production of IL-2 and
IFN-γ by PHA-stimulated peripheral blood mononuclear
cells from thalassemia patients with serum ferritin levels
higher than 4500 ng/mL (26). Other research has found
that thalassemia patients have higher serum levels of
mediators of inflammation, such as IL-6, IL-18, IL-1, and
TNF-α (27–30).
Therefore, we aimed to study the relation of repeated
blood transfusions and high serum ferritin levels on the
serum levels of IL-17, IL-21, and TGF-β on Th17 cells in
the blood of thalassemia major patients in Iran. We also
compared the results according to the patients’ clinical or
pathological status.
2. Materials and methods
Forty-three β-thalassemia major patients (17 males and 26
females) of mean age 15.8 ± 5.9 years (range 6–23) with
serum ferritin levels 460 to 7200 ng/mL over the previous
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6 months (34 children with ferritin <4500 and 9 patients
with >4500 ng/mL) participated in this study, of which
only eleven were splenectomized (seven males and four
females). The patients were referred to the immunology
laboratory from the hospitals of Jahrom University of
Medical Sciences. The patients were regularly transfused
with packed red cells every 3–4 weeks to maintain mean
hemoglobin levels above 9.8 g/dL, and were receiving
regular iron chelating therapy (deferoxamine 40 mg/kg
daily) without ascorbic acid that was similar between all
patients. The mean dose of deferoxamine was 40–50 mg/
kg per infusion over 8–12 h, 5–6 days per week in all
patients. All experiments were performed (once for each
patient) before transfusion. Patients were excluded from
this study if they had one of the following conditions:
poor deferoxamine compliance (those with less than 80%
compliance), chronic liver disease such as hepatitis B or
C infection, a history of a positive HIV test, chronic renal
or heart failure, iron chelation therapy with deferiprone,
pregnancy, and infection 2–3 weeks before. Meanwhile,
five and two patients were excluded from study because
of colds and some technical errors, respectively. Data
on age, sex, white blood cell count, red blood cell count,
hemoglobin, hematocrit, mean corpuscular volume, mean
corpuscular hemoglobin, mean corpuscular hemoglobin
concentration, platelet count, splenectomy performance,
and deferoxamine treatment were obtained from the
hospital records for patients and controls. The control
group included 43 subjects matched for age and sex (20
males and 23 females) selected randomly from healthy
individuals undergoing a check-up and routine complete
blood cell count. The controls were of mean age 10 ±
5.8 years; range 3–20 years. During sample collection,
it was ensured that subjects had neither infection nor
any acute or chronic disease. Sample characteristics and
hematological findings of the β-thalassemia major patients
and healthy controls are summarized in Table 1. During
the data analyses, six from the 49 samples were excluded.
All subjects provided informed consent to participate
in the study and to allow their biological samples to be
analyzed. Approval for the study was given by the Ethics
Committee of the Shiraz University of Medical Sciences
(Jahrom, Iran).
2.1. Enzyme linked immunosorbent assay (ELISA)
The amounts of IL-17, TGF-β, and IL-21 in the patients’ and
controls’ sera were measured at the same time by the same
technician, using ELISA kits (eBiosciences, San Diego,
CA, USA). Briefly, premixed standards were reconstituted
in PBS (pH 7.2), generating a stock concentration of
500, 1000, and 4000 pg/mL for IL-17, TGF-β, and IL21, respectively. Sensitivity for IL-17 was 4 pg/mL and
minimal cross-reactivity IL-17 to the recombinant human
Il-17AF heterodimer was observed at 0.4%. Sensitivity for
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Table 1. Descriptive statistics of general characteristics and hematological findings for β-thalassemia major patients and controls.
Characteristics and hematological findings

Patients (n = 43)

Controls (n = 43)

P

Age (years)

15.8 ± 5.9

10 ± 5.8

-

Male

17 (39.5%)

28 (65.1%)

0.5

Female

26 (60.5%)

15 (34.9%)

-

White blood count × 109/L

9.5 ± 6.3

9.1 3.3

0.19

Red blood cell count × 1012/ L

3.6 ± 0.5

4.6 ± 0.6

<0.0001

Hemoglobin (g/L)

9.8 ± 1.0

12.8 ± 1.7

<0.0001

Hematocrit (%)

29.3 ± 5.2

37.4 ± 5.0

<0.0001

Mean corpuscular volume (fL)

79.9 ± 9.7

80.7 ± 8.5

0.23

Mean corpuscular hemoglobin (pg/cell)

26.5 ± 2.3

27.9 ± 3.4

0.0003

Mean corpuscular hemoglobin concentration (27–33.3 g/dL)

32.9 ± 1.5

34.0 ± 2.5

0.004

Platelet count (150–400 × 10 / L)

361.6 ± 199.5

236.4 ± 115.5

<0.0001

Splenectomy (%)

28.9

-

-

Deferoxamine treatment (week/ night)

3±1

-

-

Deferoxamine dosage (mg/kg)

40–50

-

-

9

both IL-21 and TGF-β was 8 pg/mL. The standard stocks
were serially diluted in Reagent Diluent to generate 7
points for the standard curves. Diluted Capture Antibody
was added to a 96-well, flat-bottomed, polystyrene
microtiter plate, at final volume of 100 μL. The plates were
sealed and incubated overnight at room temperature, then
washed with Wash Buffer. Premixed standards or samples
(100 μL) were added to each well, which covered with an
adhesive strip and incubated for overnight at 4 °C. After
incubation and washing, 100 μL of the premixed Detection
Antibody was added to each well and the plate was covered
with a new adhesive strip and incubated for 2 h at room
temperature. After incubation and washing, StreptavidinHRP was added to each well (100 μL). The incubation
was terminated after 20 min at room temperature and the
plates were kept away from direct light. Then 50 μL of Stop
Solution was added to each well, and the optical density of
each well was immediately determined using a microplate
reader set to 450 nm. The results were expressed in pg/mL.
2.2. Statistical analysis
The serum levels of IL-17, IL-21, and TGF-β in the
peripheral blood were compared to the corresponding
values from control samples using nonparametric MannWhitney tests by SPSS v. 11.5 (SPSS, Chicago, IL, USA).
Finally, correlations between different cell populations
were evaluated using Spearman correlation coefficients.
The variable levels were evaluated by means of Prism

4 software (San Diego CA, USA, 2003). P < 0.05 was
regarded as significant in all statistical analyses.
3. Results
3.1. Cytokine assay in patient and healthy groups
Serum levels of IL-17 among patients were significantly
increased compared to the controls (25.76 ± 4.15 vs.
19.91 ± 2.79 pg/mL; P = 0.005) (Figure 1A). We noted
significant differences in the serum levels of IL-17 in
peripheral blood of patients with low ferritin (less than
4500 ng/mL) and splenectomized and nonsplenectomized
patients compared to the healthy controls (28.21 ± 5.17,
30.94 ± 13.38, and 22.79 ± 3.69 vs. 19.91 ± 2.79 pg/mL; P =
0.004, 0.04, and 0.01, respectively). However, there was no
significant difference in the serum level of IL-17 between
the healthy controls compared to patients with high
ferritin (higher than 4500 ng/mL) (P > 0.05). In addition,
in patients none of the hematological findings showed
significant difference in IL-17 serum level (Table 2). The
levels of IL-17 in splenectomized and nonsplenectomized
patients, and between patients with low ferritin and
high ferritin were similar (P > 0.05). These results are
summarized in Table 3.
Comparison of the findings shows significantly higher
levels of TGF-β in all patients, patients with low ferritin and
high ferritin, and splenectomized and nonsplenectomized
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Figure 1. Serum level of IL-17, TGF-β, and IL-21 in the peripheral blood of patients with thalassemia patients and normal controls.
(A) Significant differences were found in the serum levels of IL-17 in the peripheral blood of all patients, patients with low ferritin,
splenectomy, and nonsplenectomy compared to the healthy controls. (B) TGF-β serum levels were significantly higher in the peripheral
blood of all patients, patients with low ferritin, high ferritin, splenectomy, and nonsplenectomy compared to the healthy controls. (C)
No significant difference was found in the serum levels of IL-21 among patients compared to the healthy controls. Presented data were
analyzed with the nonparametric two-tailed Mann–Whitney test and the horizontal lines show the median of the groups. *P < 0.05 and
**P < 0.01.
Table 2. Correlations between ferritin, Hb, and HCT with IL-17,
TGF-β, and IL-21 serum levels in patients with thalassemia.

Ferritin

Hb

HCT

IL-17

TGF-β

IL-21

r

–0.08

–0.48

–0.22

P

0.59

0.76

0.14

r

0.10

–0.28

–0.13

P

0.52

0.06

0.40

r

–0.13

–0.19

–0.24

P

0.93

0.21

0.12

Hb; Hemoglobin, HCT; Hematocrit
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patients than in healthy volunteers (546.35 ± 58.27,
546.15 ± 62.39, 527.96 ± 176.26, 632.74 ± 65.30, and
469.67 ± 72.15 vs. 171.58 ± 51.68 pg/mL; P = 0.0002,
0.001, 0.01, 0.005, and 0.007, respectively) (Figure 1B).
However, there is no significant difference in the serum
levels of TGF-β in patients with low ferritin compared to
those with high ferritin, or between splenectomized and
nonsplenectomized patients (P > 0.05) (Table 3). We noted
no correlation between TGF-β serum level with ferritin,
Hb, or HCT in patients (r = –0.48, –0.28, and –0.19,
respectively; P > 0.05) (Table 2).
Serum levels of IL-21 in patients did not differ
compared to the control group (597.24 ± 51.37 vs. 796.18
± 83.71 pg/mL; P = 0.2). Moreover, among the patients
with low ferritin and high ferritin, and splenectomized
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Table 3. The serum concentrations of IL-17, TGF-β, and IL-21 in patients with thalassemia in low ferritin, high ferritin, splenectomy,
and nonsplenectomy groups. Presented data were analyzed with the nonparametric two-tailed Mann–Whitney test.
Low ferritin b
Splenectomy

Nonsplenectomy

Splenectomy

Nonsplenectomy

Mean ± SEM

44.19 ± 15.97

21.63 ± 2.51

-d

31.86 ± 14.95

Median

27.05

17.25

-d

13.28

P

n.s.

IL-17

a

TGF-β

n.s.

a

Mean ± SEM

490.40 ± 106.72

593.97 ± 88.22

-d

494.38 ± 108.78

Median

671.34

653.88

-d

616.64

P

n.s.

IL-21

a

High ferritin c

n.s.

a

Mean ± SEM

565.65 ± 87.70

585.86 ± 49.45

-d

639.52 ± 172.78

Median

490.34

540.55

-d

465.24

P

n.s.

n.s.

pg/mL, b<4500 ng/mL, c>4500 ng/mL, d there was no value, n.s.: Nonsignificant

and nonsplenectomized patients, the serum levels of IL21 were not different compared to those of the controls
(620.42 ± 61.41, 490.34 ± 89.10, 778.20 ± 147.40, and 517.04
± 43.26 vs. 796.18 ± 83.71 pg/mL; P > 0.05) (Figure 1C). In
addition, there was no significant difference in the serum
levels of IL-21 in patients with low ferritin compared to
those with high ferritin, or between splenectomized with
nonsplenectomized patients (P > 0.05) (Table 3). Similar
to previous cytokines, IL-21 levels in patients did not
correlate with level of ferritin, Hb, or HCT (r = –0.22, 0.13,
and –0.24, respectively; P > 0.05) (Table 2).
4. Discussion
In this study, serum levels of IL-17, IL-21, and TGF-β in
the peripheral blood of patients with β-thalassemia were
analyzed. The data indicated higher levels of IL-17 and
TGF-β, but not IL-21, in the patients compared to the
controls, suggesting an inflammatory status associated
with the suppression of T cell immune response. This is in
agreement with Balouchi et al.’s study showing increased
TGF-β and IL-17 in thalassemia patients, which means
that T cells show a stimulated phenotype, while their
activity has been suppressed (31).
The effects of splenectomy, iron overload, and
hematologic factors on the immune response of
β-thalassemia major patients were also investigated. In
this study, no correlation was observed between ferritin

and the cytokine levels in thalassemia patients, whereas
increased IL-17 serum levels in patients with low ferritin,
splenectomy, and nonsplenectomy were found. In addition,
it was shown that TGF-β serum levels in splenectomized
and nonsplenctomized, and low ferritin and high ferritin
patients were higher than in the healthy controls. Weiss
et al. reported that iron directs the immune response
toward a Th2 response, which is unfavorable for fighting
bacterial or viral infections (3). Gharagozloo et al. also
demonstrated a significant decreasing in IL-2, IFN-γ, and
IL-4 production by activated lymphocytes from patients
with β-thalassemia compared to the normal group (26).
However, Salasa and Zoumbos showed that stimulated
blood mononuclear cells from thalassemia patients
produced more IFN-γ than their control group. This might
be due to infections in β-thalassemia patients (32).
In the present study, serum ferritin levels in ten patients
were higher than 4500 ng/mL and those of the rest were
less than 4500 ng/mL. Although the mean serum levels
of IL-17, IL-21, and TGF-β were not different between
ferritin subgroups, high serum levels of IL-17 in patients
with serum ferritin levels less than 4500 ng/mL compared
to those with levels higher than 4500 ng/mL rather than
healthy controls were found. This is somewhat in keeping
with the findings of Gharagozloo’s study, which reported
low production of IL-2 and IFN-γ in patients with serum
ferritin levels higher than 4500 ng/mL in response to PHA
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stimulation (26). Accordingly, iron overload may suppress
Th1 immunity in thalassemia patients with increased
serum ferritin levels (3,33,34).
Cytokine serum levels between splenectomized and
nonsplenectomized patients were similar in our study.
However, other studies reported that patients with
splenectomy have marked absolute lymphocytosis. This
suggests that the spleen could play some part in the
regulation of lymphocyte counts and act as a reservoir for
lymphocytes produced in the body but it could not affect
cytokine levels (26).
The effect of Th17 should be considered within the
context of Treg function, as the two cell subsets of the
immune response have evolved to fine-tune immune
suppression versus immune potentiation. In this
scenario, our finding of increased expression of IL-17 as
proinflammatory cytokine in peripheral blood from a
group of patients that contained many children without
spelenectomy can be interpreted as a reflection of a
proinflammatory response. Furthermore, higher levels of
TGF-β in either the current study or other studies (31,35)
in thalassemia patients compared to the control group
show TGF-β is mainly produced by Treg, which mediates
immune suppression to limit immunopathogenesis
associated with chronic inflammation and persistent
infections. Therefore, increased production of IL-17
and TGF-β might contribute to abnormalities in iron
metabolism and it is probably due to overstimulation of

Th17. In fact, iron deposition in the reticuloendothelial
system such as macrophages and epithelial cells may
influence the regulation of Th17 responses in thalassemia
patients and result in higher levels of its cytokines in the
circulation. On the other hand, multiple blood transfusions
may cause the immune system in β-thalassemia patients
to be under constant alloantigen stimulation, despite the
suppressed immune responses due to iron overload (36).
Taken together, it seems T lymphocytes are activated
in multitransfused β-thalassemia major patients, though
T-cell suppression due to TGF-β is seen too. These
observations may have implications for the associations
between repeated immune activation and premature aging
of the immune system that result in exhaustion of immune
resources (37). On the other hand, blood transfusion and
chronic immune activation might induce Treg cells, which
suppress T-cell effector functions. Finally, this cytokine
profile clinically can be used as a related marker for
assessing disease severity and an indicator in following the
disease and consequently therapeutic intervention.
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